38 completed, 13 unknown, 12 terminated, 9 withdrawn. 34 Phase 2, 26 Phase 3, 12 Phase 1, 11 Phase 4, 7 Not applicable.
Follow IVIG: new trials by email Literature Review of IVIG trials Research Report on IVIG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| IVIG Boya: Safety, Efficacy, and Pharmacokinetics Boya IVIG - Primary Immunodeficiency Disease | Phase 3 | Not yet recruiting | Azidus Brasil | 50 | 2026-09-01 | 2026-06-03 |
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| Non Inferiority KawasakI Trial With Anakinra Anakinra, Intravenous Immunoglobulins, Human - Kawasaki Disease, Anakinra | Phase 4 | Withdrawn | Meyer Children's Hospital IRCCS | 2026-04-01 | 2026-10-26 | |
| A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP empasiprubart, IVIg, empasiprubart-placebo - Chronic Inflammatory Demyelinating Polyneuropathy, CIDP | Phase 3 | Recruiting | argenx | 218 | 2025-08-22 | 2026-10-30 |
| Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) Immune Globulin Intravenous - Myeloma, Non Hodgkin's Lymphoma | Phase 2 / Phase 3 | Recruiting | Monash University | 900 | 2025-04-28 | 2025-10-07 |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) riliprubart, Placebo, IVIg - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | Sanofi | 160 | 2024-08-21 | 2026-10-19 |
| Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC Poly ICLC, IVIG - Stage IV NSCLC | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2024-06-04 | 2024-09-19 | |
| Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG IVIG - Primary Immunodeficiency Disease | Phase 3 | Unknown | Azidus Brasil | 50 | 2024-04-01 | 2024-03-12 |
| IVIG in Painful Sensory Neuropathy Intravenous immunoglobulin, Placebo - Sensory Neuropathy, Small Fiber Neuropathy | Phase 4 | Not yet recruiting | Sorlandet Hospital HF | 20 | 2024-02-01 | 2023-12-27 |
| Prednisone Plus IVIg vs. Prednisone for ITP During Pregnancy Prednisone, IVIg - Immune Thrombocytopenia | Phase 2 | Unknown | Peking University People's Hospital | 100 | 2023-10-19 | 2024-08-29 |
| Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections IVIG - Viremia, Bacteremia | Phase 4 | Unknown | Shanghai Changzheng Hospital | 40 | 2023-04-01 | 2023-04-05 |
| Role of Immunoglobulin in Male Infertility IVIG - Male Subfertility | Not applicable | Unknown | Dr Salma kafeel Qureshi | 50 | 2023-04-01 | 2024-05-21 |
| Validation of Cutaneous Nerve Demyelination in Diagnosis and Treatment of CIDP IVIg - CIDP | Terminated | Vanderbilt University Medical Center | 2 | 2023-02-28 | 2025-06-05 | |
| The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics Sham, Therapeutic Plasma Exchange, IVIG - Aging | Phase 3 | Unknown | Dobri Kiprov | 40 | 2022-09-12 | 2024-08-02 |
| Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Gamunex-C, Albumin - Immune-Mediated Necrotizing Myopathy | Phase 2 | Withdrawn | University of Washington | 2022-05-01 | 2022-10-24 | |
| Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx Imlifidase, PLEX, IVIg - Kidney Transplantation in Highly Sensitized Patients | Phase 3 | Completed | Hansa Biopharma AB | 64 | 2021-10-14 | 2026-04-30 |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| Intravenous Immunoglobulin and Prednisolone for RPL After ART. Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring), Prednisolone Tablets, Human Albumin Solution - Habitual Abortion, Recurrent Pregnancy Loss | Phase 2 | Completed | Aalborg University Hospital | 80 | 2021-01-28 | 2025-11-24 |
Showing 20 of 84. Sign in to see all of them.
Mucocutaneous Lymph Node Syndrome (6) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (6) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · COVID-19 (3) · Guillain-Barre Syndrome (3) · Primary Immunodeficiency Diseases (3) · Purpura, Thrombocytopenic, Idiopathic (3) · Agammaglobulinemia (2) · Coronavirus Infections (2) · Epilepsy (2) · Infections (2) · Kidney Failure, Chronic (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Neoplasms (2)
Grifols Therapeutics LLC (5) · Children's Hospital of Fudan University (4) · Northwestern University (3) · Annexon, Inc. (2) · Azidus Brasil (2) · NYU Langone Health (2) · Seoul National University Hospital (2) · Tabriz University of Medical Sciences (2) · The University of Hong Kong (2) · University of Alabama at Birmingham (2) · University of Cambridge (2) · Aalborg University Hospital (1) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1)
United States (43) · China (9) · Canada (8) · Czechia (5) · Germany (5) · Israel (5) · United Kingdom (5) · Sweden (4) · Argentina (3) · Australia (3) · Austria (3) · Denmark (3) · France (3) · Greece (3) · Hungary (3)
Richard Burt, MD (3) · George Sakoulas, MD (2) · Luciana Ferrara (2) · Mehdi Yousefi, Immunologist (2) · Mohammad Nouri, Ph.D (2) · Alasdair Coles, 01223 762016 (1) · Alasdair Coles, PhD FRCP (1) · Amanda Grimes, MD (1) · Anil K Chandraker, MD (1) · Avroy A. Fanaroff, MD (1) · Balamurali K Ambati, M.D., Ph.D., M.B.A. (1) · Benyan Luo, Ph.D (1) · Bettina Cuneo, MD (1) · Beverly C Walters, MD (1) · Carlos Rodriguez-Galindo, MD (1)
PMID 12765346, PMID 17166218, PMID 19710204, PMID 19819893, PMID 21095154, PMID 22889462, PMID 24628478, PMID 18178525, PMID 18645164, PMID 19260050, PMID 19365055, PMID 19496683, PMID 20386074, PMID 20457948, PMID 20647554, PMID 20837852, PMID 21745374, PMID 23375965, PMID 23450336, PMID 24088271, PMID 25090414, PMID 26083430, PMID 26844479, PMID 29202623, PMID 31174586, PMID 31324444, PMID 32301258, PMID 32612255, PMID 33568350, PMID 33593867, PMID 33601937, PMID 34452956, PMID 34715057, PMID 34895290, PMID 35933358, PMID 36137638, PMID 36809199, PMID 37947364, PMID 38509495, PMID 40424097, PMID 40458542, PMID 41071936, PMID 41123939, PMID 41263919, PMID 41985133, PMID 8133853, PMID 9686724
2023 (1), U01AI077867 (1), U01HD019897 (1), U10HD021364 (1), U10HD021373 (1), U10HD021385 (1), U10HD021397 (1), U10HD021415 (1), UG1CA189828 (1)